GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Futura Medical PLC (OTCPK:FAMDF) » Definitions » Institutional Ownership

FAMDF (Futura Medical) Institutional Ownership : 3.40% (As of Dec. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Futura Medical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Futura Medical's institutional ownership is 3.40%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Futura Medical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Futura Medical's Float Percentage Of Total Shares Outstanding is 0.00%.


Futura Medical Institutional Ownership Historical Data

The historical data trend for Futura Medical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Futura Medical Institutional Ownership Chart

Futura Medical Historical Data

The historical data trend for Futura Medical can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 3.40 3.40 3.40 3.40 3.40 3.40 3.40 3.40 3.38 3.38

Futura Medical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Futura Medical Business Description

Traded in Other Exchanges
Address
40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives a majority of its revenue from the United Kingdom and the European Union.